ZC2HC1C

Summary

ZC2HC1C (zinc finger C2HC-type containing 1C, HGNC:20354) is a protein-coding gene on chromosome 14q24.3, encoding Zinc finger C2HC domain-containing protein 1C (Q53FD0).

Predicted to enable zinc ion binding activity.

Source: NCBI Gene 79696 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Limited, GenCC)
• GWAS associations: 2
• Clinical variants (ClinVar): 74 total
• MANE Select transcript: NM_024643

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:20354
Approved symbol	ZC2HC1C
Name	zinc finger C2HC-type containing 1C
Location	14q24.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000119703
Ensembl biotype	protein_coding
Entrez	79696

Gene structure

Transcript identifiers

Ensembl transcripts: 18 — 15 protein_coding, 2 protein_coding_CDS_not_defined, 1 nonsense_mediated_decay

ENST00000238686, ENST00000439583, ENST00000524913, ENST00000525046, ENST00000526130, ENST00000526748, ENST00000532198, ENST00000534151, ENST00000554763, ENST00000673663, ENST00000673981, ENST00000674017, ENST00000674086, ENST00000674094, ENST00000674097, ENST00000875427, ENST00000875428, ENST00000946640

RefSeq mRNA: 3 — MANE Select: NM_024643 NM_001042430, NM_001330191, NM_024643

CCDS: CCDS41972, CCDS45138, CCDS81829

Canonical transcript exons

ENST00000524913 — 3 exons

Exon	Start	End
ENSE00001286339	75070555	75071911
ENSE00002142361	75077532	75079988
ENSE00002143226	75069641	75069749

Expression profiles

Bgee: expression breadth ubiquitous, 181 present calls, max score 95.34.

FANTOM5 (CAGE): breadth broad, TPM avg 1.4127 / max 246.2924, expressed in 542 samples.

FANTOM5 promoters (3 alternative TSS)

Promoter ID	TPM avg	Samples expressed
140601	1.1352	441
140599	0.2358	104
140600	0.0417	11

Top tissues by expression

285 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
left testis	UBERON:0004533	95.34	gold quality
right testis	UBERON:0004534	94.96	gold quality
testis	UBERON:0000473	92.96	gold quality
adult organism	UBERON:0007023	88.68	gold quality
right uterine tube	UBERON:0001302	88.22	gold quality
bronchial epithelial cell	CL:0002328	87.16	gold quality
epithelium of bronchus	UBERON:0002031	85.08	gold quality
corpus epididymis	UBERON:0004359	83.97	gold quality
bronchus	UBERON:0002185	83.51	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	82.25	gold quality
olfactory segment of nasal mucosa	UBERON:0005386	80.42	gold quality
apex of heart	UBERON:0002098	79.88	gold quality
right lobe of thyroid gland	UBERON:0001119	79.66	gold quality
cauda epididymis	UBERON:0004360	78.60	gold quality
right lobe of liver	UBERON:0001114	78.17	gold quality
left lobe of thyroid gland	UBERON:0001120	78.14	gold quality
adenohypophysis	UBERON:0002196	78.05	gold quality
sperm	CL:0000019	78.04	gold quality
male germ cell	CL:0000015	77.54	gold quality
thyroid gland	UBERON:0002046	77.35	gold quality
pituitary gland	UBERON:0000007	77.03	gold quality
mucosa of paranasal sinus	UBERON:0005030	76.67	silver quality
caput epididymis	UBERON:0004358	75.98	gold quality
body of pancreas	UBERON:0001150	75.97	gold quality
heart left ventricle	UBERON:0002084	75.97	gold quality
mucosa of transverse colon	UBERON:0004991	75.95	gold quality
islet of Langerhans	UBERON:0000006	75.57	gold quality
cardiac ventricle	UBERON:0002082	75.36	gold quality
gastrocnemius	UBERON:0001388	75.20	gold quality
pancreas	UBERON:0001264	74.60	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	3.57

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

101 targeting ZC2HC1C, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-3925-3P	100.00	69.95	1237
HSA-MIR-4514	99.99	67.10	1870
HSA-MIR-196A-1-3P	99.99	72.15	2772
HSA-MIR-1184	99.99	68.19	1458
HSA-MIR-548P	99.98	72.25	3784
HSA-MIR-1468-3P	99.96	72.74	3797
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-5195-3P	99.92	70.92	1877
HSA-MIR-145-5P	99.92	71.13	1836
HSA-MIR-6499-3P	99.90	66.38	1212
HSA-MIR-3919	99.87	69.45	2489
HSA-MIR-12119	99.87	68.35	1653
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-6817-3P	99.79	68.35	2126
HSA-MIR-548AG	99.77	69.25	1492
HSA-MIR-3156-3P	99.76	66.72	939
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-518A-5P	99.70	69.01	2209
HSA-MIR-527	99.70	69.01	2209
HSA-MIR-548AI	99.69	69.24	1494
HSA-MIR-548BA	99.69	69.14	1514
HSA-MIR-570-5P	99.69	69.24	1494
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-5004-5P	99.68	66.63	1294
HSA-MIR-7-5P	99.67	70.53	1809
HSA-MIR-10394-5P	99.65	66.83	1852
HSA-MIR-1205	99.65	66.76	1826
HSA-MIR-7156-5P	99.64	68.81	1369

Literature-anchored findings (GeneRIF, showing 1)

• Screening of candidate genes at GLC3B and GLC3C loci in Chinese primary congenital glaucoma patients with targeted next generation sequencing. (PMID:36193031)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	zc2hc1c	ENSDARG00000070526
mus_musculus	Zc2hc1c	ENSMUSG00000045064
rattus_norvegicus	Zc2hc1c	ENSRNOG00000027115

Protein

Protein identifiers

Zinc finger C2HC domain-containing protein 1C — Q53FD0 (reviewed: Q53FD0)

All UniProt accessions (5): Q53FD0, A0A669KB15, E9PMG6, H0YE08, J3KMY6

UniProt curated annotations — full annotation on UniProt →

Similarity. Belongs to the ZC2HC1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q53FD0-1	1	yes
Q53FD0-2	2

RefSeq proteins (3): NP_001035895, NP_001317120, NP_078919* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR026104	ZNF_C2HC_dom_1C	Family
IPR049899	Znf_C2HC_C3H	Domain

UniProt features (15 total): binding site 4, region of interest 3, compositionally biased region 3, chain 1, zinc finger region 1, splice variant 1, sequence conflict 1, coiled-coil region 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q53FD0-F1	61.23	0.16

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (4): 394; 406; 410; 391

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 112 (showing top): CMYB_01, CAGCAGG_MIR370, chr14q24, TGANTCA_AP1_C, GNF2_CCNA1, NRF2_Q4, AACTTT_UNKNOWN, LEE_LIVER_CANCER_E2F1_DN, CART1_01, AACTGGA_MIR145, NFE2_01, ACACTCC_MIR122A, LEE_LIVER_CANCER_MYC_TGFA_DN, LEE_LIVER_CANCER_MYC_DN, DODD_NASOPHARYNGEAL_CARCINOMA_DN

GO Biological Process (0):

GO Molecular Function (3): zinc ion binding (GO:0008270), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (0):

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
transition metal ion binding	1
binding	1
cation binding	1

Protein interactions and networks

STRING

626 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZC2HC1C	OR5T1	Q8NG75	571
ZC2HC1C	RPS6KL1	Q9Y6S9	544
ZC2HC1C	MLH3	P49751	449
ZC2HC1C	OR2W1	Q9Y3N9	447
ZC2HC1C	VWA3A	A6NCI4	446
ZC2HC1C	NEK9	Q8TD19	442
ZC2HC1C	C5orf34	Q96MH7	433
ZC2HC1C	MEDAG	Q5VYS4	433
ZC2HC1C	ZNF557	Q8N988	432
ZC2HC1C	SERPINB11	Q96P15	432
ZC2HC1C	MIER2	Q8N344	431
ZC2HC1C	ZNF721	Q8TF20	417
ZC2HC1C	CCDC32	Q9BV29	397
ZC2HC1C	ZNF358	Q9NW07	392
ZC2HC1C	PAMR1	Q6UXH9	386

IntAct

70 interactions, top by confidence:

A	B	Type	Score
KRT15	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.670
ZC2HC1C	MTUS2	psi-mi:“MI:0915”(physical association)	0.670
TFIP11	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.670
ZC2HC1C	KRT15	psi-mi:“MI:0915”(physical association)	0.670
ZC2HC1C	TFIP11	psi-mi:“MI:0915”(physical association)	0.670
MTUS2	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.670
PNMA1	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.600
ZC2HC1C	PNMA1	psi-mi:“MI:0915”(physical association)	0.600
ZC2HC1C	FSD2	psi-mi:“MI:0915”(physical association)	0.560
GFAP	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
TRIM27	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
ZC2HC1C	SFN	psi-mi:“MI:0915”(physical association)	0.560
TRIM23	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
TRAF2	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
TRAF1	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
KRT40	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
BANP	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
ZC2HC1C	CBY2	psi-mi:“MI:0915”(physical association)	0.560
HOOK2	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
CCDC136	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560
ZC2HC1C	SPAG5	psi-mi:“MI:0915”(physical association)	0.560
RABGEF1	ZC2HC1C	psi-mi:“MI:0915”(physical association)	0.560

BioGRID (110): ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid), ZC2HC1C (Two-hybrid)

ESM2 similar proteins: A0A1I8MUL8, A0A1L8H8C0, A0A1L8HFX9, A2AG58, A2AJT9, B9UYK6, C5IY45, E9Q309, E9Q4F7, O94687, P0DW16, P31629, P61129, P78332, P97868, Q01613, Q08D57, Q09JY9, Q17QQ9, Q27IV2, Q2T9M9, Q498L0, Q4R731, Q53FD0, Q5F3P8, Q5JSZ5, Q5LJZ2, Q5PPL1, Q5R6I3, Q5SW79, Q5T481, Q5VT06, Q62504, Q66J90, Q6IMN6, Q6P9P0, Q6UB99, Q7Z6E9, Q865B7, Q8BYK8

Diamond homologs: A4FUE7, Q22122, Q32KN7, Q53FD0, Q5PPV5, Q5REC0, Q5TFG8, Q618K0, Q6AYP4, Q7SXT7, Q8BJH1, Q8CCG1, Q96GY0, Q9BGW4, Q9D534, Q5R498

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

74 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	61
Likely benign	9
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3634 predictions. Top by Δscore:

Variant	Effect	Δscore
14:75087231:C:CC	acceptor_gain	1.0000
14:75097267:TTAT:T	acceptor_gain	1.0000
14:75100988:TCA:T	donor_loss	1.0000
14:75100989:CA:C	donor_loss	1.0000
14:75100990:A:AC	donor_gain	1.0000
14:75100991:C:CC	donor_gain	1.0000
14:75100991:C:CT	donor_loss	1.0000
14:75100991:CCAT:C	donor_gain	1.0000
14:75101149:TCGCT:T	acceptor_gain	1.0000
14:75101150:CGCT:C	acceptor_gain	1.0000
14:75101150:CGCTC:C	acceptor_gain	1.0000
14:75101152:CT:C	acceptor_gain	1.0000
14:75101152:CTCTG:C	acceptor_loss	1.0000
14:75101153:TCTG:T	acceptor_gain	1.0000
14:75101154:C:A	acceptor_loss	1.0000
14:75101154:C:CC	acceptor_gain	1.0000
14:75101154:C:G	acceptor_gain	1.0000
14:75101155:T:A	acceptor_loss	1.0000
14:75101166:C:CT	acceptor_gain	1.0000
14:75101167:A:T	acceptor_gain	1.0000
14:75101650:AACTT:A	donor_loss	1.0000
14:75101651:ACTTA:A	donor_loss	1.0000
14:75101652:CTTA:C	donor_loss	1.0000
14:75101653:TTAC:T	donor_loss	1.0000
14:75101654:TACC:T	donor_loss	1.0000
14:75101655:A:AC	donor_gain	1.0000
14:75101655:AC:A	donor_gain	1.0000
14:75101655:ACCA:A	donor_loss	1.0000
14:75101655:ACCAT:A	donor_gain	1.0000
14:75101656:C:CG	donor_gain	1.0000

AlphaMissense

3001 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
14:75071834:T:C	F421L	0.996
14:75071836:T:A	F421L	0.996
14:75071836:T:G	F421L	0.996
14:75071760:G:C	R396P	0.991
14:75071759:C:A	R396S	0.990
14:75071766:T:C	F398S	0.988
14:75071789:C:G	H406D	0.983
14:75071835:T:G	F421C	0.983
14:75071791:C:A	H406Q	0.982
14:75071791:C:G	H406Q	0.982
14:75071766:T:G	F398C	0.981
14:75071744:T:C	C391R	0.980
14:75071765:T:C	F398L	0.978
14:75071767:C:A	F398L	0.978
14:75071767:C:G	F398L	0.978
14:75071801:T:A	C410S	0.978
14:75071802:G:C	C410S	0.978
14:75071827:G:C	R418S	0.978
14:75071827:G:T	R418S	0.978
14:75071861:G:C	G430R	0.977
14:75071744:T:A	C391S	0.976
14:75071745:G:C	C391S	0.976
14:75071754:G:A	C394Y	0.976
14:75077558:G:C	W455C	0.976
14:75077558:G:T	W455C	0.976
14:75071753:T:A	C394S	0.975
14:75071754:G:C	C394S	0.975
14:75071801:T:C	C410R	0.975
14:75071803:C:G	C410W	0.975
14:75071802:G:A	C410Y	0.974

dbSNP variants (sampled 300 via entrez): RS1000008765 (14:75076708 T>C), RS1000060993 (14:75077105 T>C), RS1000300669 (14:75074258 T>C), RS1000336708 (14:75070589 C>A,T), RS1000686640 (14:75078954 G>C), RS1000738359 (14:75079319 G>GA), RS1001273923 (14:75068177 G>A), RS1001737679 (14:75074896 T>C), RS1002023672 (14:75073020 TCCC>T), RS1002275324 (14:75072022 C>T), RS1002351165 (14:75078423 A>G), RS1002405040 (14:75078754 T>G), RS1002740591 (14:75076273 T>G), RS1002775717 (14:75068894 G>C), RS1002958151 (14:75075086 C>T)

Disease associations

OMIM: gene `` | disease phenotypes:

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Limited	Autosomal recessive

Mondo (1): neurodevelopmental disorder (MONDO:0700092)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST006940_131	Neurociticism	1.000000e-13
GCST010002_156	Refractive error	7.000000e-25

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

23 total (human), top 23 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
bisphenol A	decreases methylation, increases expression	2
dicrotophos	decreases expression	1
methylmercuric chloride	decreases expression	1
S-(1,2-dichlorovinyl)cysteine	affects response to substance, increases expression	1
abrine	increases expression	1
bisphenol S	decreases methylation	1
jinfukang	increases expression	1
(+)-JQ1 compound	decreases expression	1
Temozolomide	decreases expression	1
Sunitinib	decreases expression	1
Air Pollutants	increases abundance, increases expression	1
Benzo(a)pyrene	decreases methylation	1
Cadmium	decreases expression, increases abundance	1
Doxorubicin	decreases expression	1
Lipopolysaccharides	affects response to substance, increases expression	1
Quercetin	decreases expression	1
Smoke	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1
Cyclosporine	decreases expression	1
Cadmium Chloride	decreases expression, increases abundance	1
Okadaic Acid	increases expression	1
Copper Sulfate	decreases expression	1
Particulate Matter	increases abundance, increases expression	1

Clinical trials (associated diseases)

202 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism
NCT03229928	Not specified	COMPLETED	Clinical Testing of a Real-Time Behavior Measurement Tool: Measuring Outcomes for CHAnge
NCT03232489	Not specified	UNKNOWN	Study for the Evaluation of the Feasibility of Applying Advanced MRI Scanning in Pediatric Clinical Practice